Overview

Pediatric brain tumors and cerebrovascular disorders are two different sets of diseases however they share some similarities, such as vascular anomalies and challenging detection.

Ed Smith's lab is interested in secreted Axon Guidance Factors as targets and biomarkers for these pathologies. As postdoc fellow in the Smith lab, Julie's research focuses on the involvement of Netrins family in the hypoxia-dependent invasion and angiogenesis in pediatric brain tumors. The goal of this project is to understand better the hypoxia-related tumor resistance and to treat these invasive and highly resistant tumors.

Julie has expertise in intracranial surgery, she performs orthotopic xenografts of brain tumor cells in mice to study tumor growth and invasiveness in response to different treatments.

Background

Julie Sesen obtained her Ph.D. in Oncology in 2013 at the Cancer Research Center of Toulouse in France. Her research in Pr. Elizabeth Moyal and Dr. Nicolas Skuli's lab focused on the role of translation initiation factors in the proliferation and radioresistance of glioblastoma.

In 2017, Julie joined the lab of Edward Smith, MD., Ph.D. as a Research Fellow at the Vascular Biology Program, Boston Children's Hospital. She leads different research projects and collaborations and has expertise in mentoring research assistants.

Julie is member of the board of the BCH Postdoc Association since November 2017 and she is now the co-Chair of the Public Affairs committee and the treasurer of the Postdoc Association. Besides research, Julie loves latin music and dances. She also loves exploring new areas around Boston and traveling around the world.

Researcher Services

Researcher Areas

  • Pediatric Brain Tumors
  • Cerebrovascular Disorders

Researcher Programs

Researcher Labs

PUBLICATIONS

Publications powered by Harvard Catalyst Profiles

  1. Casaos J, Huq S, Lott T, Felder R, Choi J, Gorelick N, Peters M, Xia Y, Maxwell R, Zhao T, Ji C, Simon T, Sesen J, Scotland SJ, Kast RE, Rubens J, Raabe E, Eberhart CG, Jackson EM, Brem H, Tyler B, Skuli N. Ribavirin as a potential therapeutic for atypical teratoid/rhabdoid tumors. Oncotarget. 2018 Jan 30; 9(8):8054-8067. View abstract
  2. Malric L, Monferran S, Gilhodes J, Boyrie S, Dahan P, Skuli N, Sesen J, Filleron T, Kowalski-Chauvel A, Cohen-Jonathan Moyal E, Toulas C, Lemarié A. Interest of integrins targeting in glioblastoma according to tumor heterogeneity and cancer stem cell paradigm: an update. Oncotarget. 2017 Oct 17; 8(49):86947-86968. View abstract
  3. Sesen J, Casaos J, Scotland SJ, Seva C, Eisinger-Mathason TS, Skuli N. The Bad, the Good and eIF3e/INT6. Front Biosci (Landmark Ed). 2017 01 01; 22:1-20. View abstract
  4. Volpin F, Casaos J, Sesen J, Mangraviti A, Choi J, Gorelick N, Frikeche J, Lott T, Felder R, Scotland SJ, Eisinger-Mathason TSK, Brem H, Tyler B, Skuli N. Use of an anti-viral drug, Ribavirin, as an anti-glioblastoma therapeutic. Oncogene. 2017 05 25; 36(21):3037-3047. View abstract
  5. Sesen J, Dahan P, Scotland SJ, Saland E, Dang VT, Lemarié A, Tyler BM, Brem H, Toulas C, Cohen-Jonathan Moyal E, Sarry JE, Skuli N. Metformin inhibits growth of human glioblastoma cells and enhances therapeutic response. PLoS One. 2015; 10(4):e0123721. View abstract
  6. Krock BL, Eisinger-Mathason TS, Giannoukos DN, Shay JE, Gohil M, Lee DS, Nakazawa MS, Sesen J, Skuli N, Simon MC. The aryl hydrocarbon receptor nuclear translocator is an essential regulator of murine hematopoietic stem cell viability. Blood. 2015 May 21; 125(21):3263-72. View abstract
  7. Sesen J, Cammas A, Scotland SJ, Elefterion B, Lemarié A, Millevoi S, Mathew LK, Seva C, Toulas C, Moyal EC, Skuli N. Int6/eIF3e is essential for proliferation and survival of human glioblastoma cells. Int J Mol Sci. 2014 Jan 29; 15(2):2172-90. View abstract